Severe Persistent Eczema in a Recipient of the Gam-COVID-Vac vaccine
  • Maryam Ameri
    Department of Forensic Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  • Meysam Abolmaali
    Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran
  • Sayed Mohammed Jawad Alwedaie
    Manama, Bahrain
  • Mohammad Nabavi
    Department of Allergy & Clinical Immunology, School of Medicine, Iran University of Medical Science, Tehran, Iran
  • Neda Rahimian
    Department of Internal Medicine, School of Medicine, Iran University of Medical Science, Tehran, Iran
  • Negin Mahmoodi
    Iran University of Medical Sciences, Tehran, Iran


COVID-19, Sputnik V, eczema


Since the beginning of the COVID-19 pandemic, efforts have been made to design safe and effective vaccines against SARS-CoV-2.
Numerous vaccines have been designed and tested in limited clinical trials in various countries. Among them, the Sputnik V vaccine has shown a relatively safe profile and, to our knowledge, has no associated major side effects. We describe the case of a 40-year-old female healthcare worker who developed severe persistent eczematous lesions on the second day after she received the first dose of the Sputnik vaccine. The eczematous lesions were refractory to an antihistamine and persisted at the 1 month follow-up. Severe persistent eczematous lesions should be viewed as a potential side effect of vaccination with the Sputnik V vaccine. Moreover, a severe allergic reaction to a COVID-2019 vaccine may indicate the vaccine is ineffective in the recipient.



  • Our World in Data. Coronavirus (COVID-19) vaccinations. Available from:
  • Worldometer. COVID-19 coronavirus pandemic.Available from:
  • Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA 2020;324(17):1723–1724.
  • Aragón TJ, Ulrich S, Fernyak S, Rutherford GW. Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963–1968. BMC Public Health 2003;3:26.
  • World Health Organisation. The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know. Available from:
  • World Health Organisation. Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19. Available from:
  • Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021;397(10275):671–681.
  • Laine C, Cotton D, Moyer DV. COVID-19 vaccine: practical clinical considerations. Ann Intern Med 2021;174(5):694.
  • CDC COVID-19 Response Team, Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14–23, 2020. MMWR Morb Mortality Wkly Rep 2021;70(2):46–51.
  • Babamahmoodi F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Mousavi SA, Ovaise G, et al. Side effects and immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. Sci Rep 2021;11(1):21464.
  • Chahla RE, Tomas-Grau RH, Cazorla SI, Ploper D, Vera Pingitore E, López MA, et al. Long-term analysis of antibodies elicited by SPUTNIK V: a prospective cohort study in Tucumán, Argentina. Lancet Reg Health Am 2022;6:100123.
  • Tukhvatulin AI, Dolzhikova IV, Shcheblyakov DV, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, et al. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adults. Lancet Reg Health Eur 2021;11:100241.
  • Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet 2021;397(10275):642–643.
  • Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A, et al. Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccines 2021;9(3):221.
  • Views: 2647
    HTML downloads: 773
    PDF downloads: 304

    Published: 2022-01-12
    Issue: 2022: Vol 9 No 1 (view)

    How to cite:
    Ameri M, Abolmaali M, Alwedaie SMJ, Nabavi M, Rahimian N, Mahmoodi N. Severe Persistent Eczema in a Recipient of the Gam-COVID-Vac vaccine. EJCRIM 2022;9 doi:10.12890/2022_003042.

    Similar Articles

    You may also start an advanced similarity search for this article.